28.DEC.2020 DD ATOS (Attossa Therapeutics)

December 28, 2020

Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossas current focus on breast cancer and COVID-19.

Market Cap: 38M
Free Float: 25M

Debt: None

Recent News:

Atossa Announces $20.0 M Underwritten Public Offering
Atossa Announces $14.0 M Registered Direct Offering Priced At-The-Market

Offering on 08.Dec and 17.Dec.2020

Guess we all know for what they need the money :-)

Expected News (Upcoming 2020 milestones include the following):

1. PR IMMINENT: File pre-IND meeting request with FDA for AT-301 nasal spray for potential at-home treatment of COVID-19 (ER 13.Nov +30 Days = 25th December 2020)

(“Our COVID-19 nasal spray program has progressed very well during the quarter, with our Phase 1 study of AT-301 nasal spray demonstrating good safety and tolerability at two different dose levels in both single and multiple dose forms over a 14-day trial period,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “We are very encouraged by these preliminary results. In the next 30 days (ER 13.Nov +30 Days = 25th December 2020) we plan to file a pre-IND meeting request with the FDA and, subject to their input, plan to immediately commence a Phase 2 study, either in the U.S. or abroad, in patients recently diagnosed with COVID-19.)

2. Commence Phase 2 study in Sweden for our Endoxifen to reduce MBD

3. Phase 2 for breast density/mammography adjuvant planned for Q1 2021

Covid-19 Therapies

Atossa has 2 programs to develop therapies to treat COVID-19:

1. AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators.

Launched in April 2020.

The program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases.

2. AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.

Atossa also intends to conduct testing to determine whether AT-301 can be used as a prophylaxis to prevent or mitigate SARS-CoV-2, with the goal that it could become a “bridge to the vaccine” and be useful in the next phase of the coronavirus pandemic.

Advisory Board